(ブルームバーグ): 米バイオテクノロジー大手モデルナは10日、呼吸器合胞体ウイルス(RSV ... 米食品医薬品局(FDA)の決定が ...
Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.
Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory ... A positive CDC decision from the agency will allow Moderna to compete in the U.S. fall ...
Synopsys VC Verification IP (VIP) for ARM® AMBA® AXI™ provides complete protocol support for AXI3™, AXI4™, AXI4-Lite™, AXI4-Stream™, ACE™, ACE-Lite™ , AHB™ and APB™ interfaces. ... Synopsys® VC ...
Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first ... older using shared clinical decision-making, meaning seniors ...
Like Spikevax, mRESVIA is based on Moderna's messenger RNA platform. While mRESVIA is not the first RSV vaccine to secure FDA approval—that designation went to GSK's Arexvy—Moderna's offering ...
Moderna's full-year 2024 sales guidance of roughly $4 billion includes revenue from its RSV vaccine ... 45% in 2023. The FDA was initially slated to make a decision on Moderna's jab on ...
The Food and Drug Administration (FDA ... virus vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.